By the same authors

From the same journal

Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis

Research output: Contribution to journalArticlepeer-review

Author(s)

  • Srinivasa P S Rao
  • Suresh B Lakshminarayana
  • Jan Jiricek
  • Marcel Kaiser
  • Ryan Ritchie
  • Elmarie Myburgh
  • Frantisek Supek
  • Tove Tuntland
  • Advait Nagle
  • Valentina Molteni
  • Pascal Mäser
  • Jeremy C Mottram
  • Michael P Barrett
  • Thierry T Diagana

Department/unit(s)

Publication details

JournalTropical medicine and infectious disease
DateAccepted/In press - 14 Feb 2020
DatePublished (current) - 17 Feb 2020
Issue number1
Volume5
Number of pages14
Original languageEnglish

Abstract

Current anti-trypanosomal therapies suffer from problems of longer treatment duration, toxicity and inadequate efficacy, hence there is a need for safer, more efficacious and 'easy to use' oral drugs. Previously, we reported the discovery of the triazolopyrimidine (TP) class as selective kinetoplastid proteasome inhibitors with in vivo efficacy in mouse models of leishmaniasis, Chagas Disease and African trypanosomiasis (HAT). For the treatment of HAT, development compounds need to have excellent penetration to the brain to cure the meningoencephalic stage of the disease. Here we describe detailed biological and pharmacological characterization of triazolopyrimidine compounds in HAT specific assays. The TP class of compounds showed single digit nanomolar potency against Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense strains. These compounds are trypanocidal with concentration-time dependent kill and achieved relapse-free cure in vitro. Two compounds, GNF6702 and a new analog NITD689, showed favorable in vivo pharmacokinetics and significant brain penetration, which enabled oral dosing. They also achieved complete cure in both hemolymphatic (blood) and meningoencephalic (brain) infection of human African trypanosomiasis mouse models. Mode of action studies on this series confirmed the 20S proteasome as the target in T. brucei. These proteasome inhibitors have the potential for further development into promising new treatment for human African trypanosomiasis.

Bibliographical note

© 2020 by the authors

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations